<div id="readability-page-1"><p>Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report)'s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $33.67 and last traded at $33.65, with a volume of 1371892 shares. The stock had previously closed at $33.06.</p><h2>Analysts Set New Price Targets</h2><p>A number of research firms recently issued reports on GMAB. Wall Street Zen raised Genmab A/S from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, November 22nd. Truist Financial  reaffirmed a &#34;buy&#34; rating and issued a $48.00 target price (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Weiss Ratings  reiterated a &#34;hold (c)&#34; rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Guggenheim raised shares of Genmab A/S from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $43.00 price target for the company in a report on Tuesday, September 23rd. Finally, Zacks Research cut shares of Genmab A/S from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Friday, October 31st. One investment analyst  has rated the stock with a Strong Buy rating, six have assigned  a Buy rating, three have assigned  a Hold rating and one  has issued  a Sell rating to the company. Based on data from MarketBeat, Genmab A/S  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $39.75.</p><p><b>Check Out Our Latest Report on GMAB</b></p><h2>Genmab A/S Trading Up 1.8%</h2><p>The company has a market cap of $21.62 billion, a price-to-earnings ratio of 14.32, a price-to-earnings-growth ratio of 1.69 and a beta of 0.90. The firm's fifty day moving average price is $30.77 and its 200-day moving average price is $26.80. </p><p>Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $975.40 million. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%.  As a group, research analysts anticipate that  Genmab A/S Sponsored ADR will post 1.45 EPS for the current year. </p><h2>Institutional Inflows and Outflows</h2><p>Several large investors have recently bought and sold shares of GMAB. JPMorgan Chase &amp; Co. grew its stake in  Genmab A/S by 17.0% during the second quarter. JPMorgan Chase &amp; Co. now owns 933,309 shares of the company's stock worth $19,282,000 after buying an additional 135,814 shares in the last quarter.  Foresight Group Ltd Liability Partnership bought a new stake in shares of  Genmab A/S during the 1st quarter worth approximately $954,000.  Squarepoint Ops LLC boosted its position in shares of  Genmab A/S by 636.3% during the 2nd quarter. Squarepoint Ops LLC now owns 94,233 shares of the company's stock worth $1,947,000 after acquiring an additional 81,434 shares in the last quarter.  Vident Advisory LLC bought a new position in  Genmab A/S in the first quarter valued at approximately $242,000.  Finally, Wealth Enhancement Advisory Services LLC acquired a new position in  Genmab A/S during the second quarter valued at approximately $257,000. 7.07% of the stock is owned by institutional investors and hedge funds. </p><h2>Genmab A/S Company Profile</h2> (Get Free Report)<p>Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company's work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.  </p><p>Genmab's portfolio includes products developed in collaboration with leading global pharmaceutical partners.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Genmab A/S</li><li>Do not delete, read immediately</li><li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Genmab A/S Right Now?</h2><p>Before you consider Genmab A/S, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.</p><p>While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GMAB

<p>Genmab A/S (NASDAQ:GMAB) reached a new 52-week high at $33.67. Analysts have mixed ratings, with a consensus of "Moderate Buy" and an average target price of $39.75. The company reported strong quarterly earnings, beating estimates with $0.65 EPS and $1.02 billion revenue. Institutional investors are actively trading the stock, which has a market cap of $21.62 billion.</p>

Genmab A/S (NASDAQ:GMAB) Reaches New 1-Year High - Still a Buy?